Applications for new adaptations of recombined human growth hormone for antho-injection were accepted

According to the announcement, short stature refers to those who are below the 3rd percentile of the normal population of the same race, age and gender, or 2 standard deviations (-2SD) in height below the average height of the normal population in a similar living environment.
According to statistics, the occurrence rate of children's short stature in China is about 3%, and idepathic dwarf is the most common type of children's short stature, refers to no systemic, endocrine, nutritional diseases or chromosomal abnormality of small stature, ISS children's birth weight and growth hormone water level is normal, ISS can be caused by a variety of currently unclear causes, accounting for about 60%-80% of all small children.
children's short stature not only brings serious harm to children's physical and mental health, interpersonal communication, social employment, etc., but also brings heavy burden to society.
recombined human growth hormone has been approved at home and abroad for the treatment of a variety of children's short body-related adaptive disorders, this application to add ISS adaptation, has been approved for listing in the United States.
At present, china has not yet approved the listing, but growth hormone for the treatment of idiotic dwarfs has been included in the Chinese Medical Association Science Journal "Short body children diagnosis and treatment guide" and "Idiotic short children diagnosis and treatment consensus statement" and other industry guidelines.
Anke Bio says its injectable recombined human growth hormone (commodity name: Ansu Meng) has been approved for listing six adaptations: 1) for slow growth in children due to endogenous growth hormone deficiency and 2) for children with Noonan syndrome Short stature; 3) for children with short stature or growth disorders caused by SHOX genetic defects; 4) for severe burns treatment; 5) for children with incomplete cartilage development; and 6) for adult short bowel syndrome, which is supported by nutrition.
This new adaptation is a rich and complementary to approved adaptive disorders, and if approved, it will be beneficial to address the clinical drug needs of children with this "consensus statement on diagnosis and treatment of idiotic short children," the Journal of Pediatric Endocrinology of Lawson Wilkins and the European Society of Pediatric Endocrinology.